Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7

被引：45

作者：

Fröhling, S ^{[1
]}

Lipka, DB ^{[1
]}

Kayser, S ^{[1
]}

Scholl, C ^{[1
]}

Schlenk, RF ^{[1
]}

Döhner, H ^{[1
]}

Gilliland, DG ^{[1
]}

Levine, RL ^{[1
]}

Döhner, K ^{[1
]}

机构：

[1] Harvard Univ, Div Hematol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA

来源：

BLOOD | 2006年 / 107卷 / 03期

关键词：

D O I：

10.1182/blood-2005-09-3644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1242 / 1243

页数：2

共 9 条

[1] A unifying mutation in chronic myeloproliferative disorders [J].

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1744-1746

[2] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia [J].

Jelinek, J ;

Oki, Y ;

Gharibyan, V ;

Bueso-Ramos, C ;

Prchal, JT ;

Verstovsek, S ;

Beran, M ;

Estey, E ;

Kantarjian, HM ;

Issa, JPJ .

BLOOD, 2005, 106 (10) :3370-3373

[3] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].

Jones, AV ;

Kreil, S ;

Zoi, K ;

Waghorn, K ;

Curtis, C ;

Zhang, LY ;

Score, J ;

Seear, R ;

Chase, AJ ;

Grand, FH ;

White, H ;

Zoi, C ;

Loukopoulos, D ;

Terpos, E ;

Vervessou, EC ;

Schultheis, B ;

Emig, M ;

Ernst, T ;

Lengfelder, E ;

Hehlmann, R ;

Hochhaus, A ;

Oscier, D ;

Silver, RT ;

Reiter, A ;

Cross, NCP .

BLOOD, 2005, 106 (06) :2162-2168

[4] On the molecular origins of the chronic myeloproliferative disorders: it all makes sense [J].

Kaushansky, K .

BLOOD, 2005, 105 (11) :4187-4190

[5] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia [J].

Levine, RL ;

Loriaux, M ;

Huntly, BJP ;

Loh, ML ;

Beran, M ;

Stoffregen, E ;

Berger, R ;

Clark, JJ ;

Willis, SG ;

Nguyen, KT ;

Flores, NJ ;

Estey, E ;

Gattermann, N ;

Armstrong, S ;

Look, AT ;

Griffin, JD ;

Bernard, OA ;

Heinrich, MC ;

Gilliland, DG ;

Druker, B ;

Deininger, MWN .

BLOOD, 2005, 106 (10) :3377-3379

[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[7] Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines [J].

Liu, RY ;

Fan, C ;

Garcia, R ;

Jove, R ;

Zuckerman, KS .

BLOOD, 1999, 93 (07) :2369-2379

[8] HEL CELLS - A NEW HUMAN ERYTHROLEUKEMIA CELL-LINE WITH SPONTANEOUS AND INDUCED GLOBIN EXPRESSION [J].

MARTIN, P ;

PAPAYANNOPOULOU, T .

SCIENCE, 1982, 216 (4551) :1233-1235

[9] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

← 1 →